title: A Phase I/II adaptive design to determine the optimal treatment regimen from a set of combination immunotherapies in high-risk melanoma.
abstract: In oncology, vaccine-based immunotherapy often investigates regimens that demonstrate minimal toxicity overall and higher doses may not correlate with greater immune response. Rather than determining the maximum tolerated dose, the goal of the study becomes locating the optimal biological dose, which is defined as a safe dose demonstrating the greatest immunogenicity, based on some predefined measure of immune response. Incorporation of adjuvants, new or optimized peptide vaccines, and combining vaccines with immune modulators may enhance immune response, with the aim of improving clinical response. Innovative dose escalation strategies are needed to establish the safety and immunogenicity of new immunologic combinations. We describe the implementation of an adaptive design for identifying the optimal treatment strategy in a multi-site, FDA-approved, phase I/II trial of a novel vaccination approach using long-peptides plus TLR agonists for resected stage IIB-IV melanoma. Operating characteristics of the design are demonstrated under various possible true scenarios via simulation studies. Overall performance indicates that the design is a practical Phase I/II adaptive method for use with combined immunotherapy agents. The simulation results demonstrate the method's ability to effectively recommend optimal regimens in a high percentage of trials with manageable sample sizes. The numerical results presented in this work include the type of simulation information that aid review boards in understanding design performance, such as average sample size and frequency of early trial termination, which we hope will augment early-phase trial design in cancer immunotherapy.
authors: Division of Translational Research & Applied Statistics, Department of Public Health Sciences University of Virginia, Charlottesville, VA 22908, USA. Electronic address: nwages@virginia.edu.
authors: Nolan A
authors: NA
authors: Wages
authors: Division of Surgical Oncology, Department of Surgery, University of Virginia, Charlottesville, VA 22904-4135, USA.
authors: Craig L
authors: CL
authors: Slingluff
authors: Division of Translational Research & Applied Statistics, Department of Public Health Sciences University of Virginia, Charlottesville, VA 22908, USA.
authors: Gina R
authors: GR
authors: Petroni
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D019496:Cancer Vaccines / Q000008:administration & dosage*; D017024:Chemotherapy, Adjuvant; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007167:Immunotherapy; D020714:Maximum Tolerated Dose; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology; D009367:Neoplasm Staging; D012107:Research Design; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology; D051193:Toll-Like Receptors / Q000819:agonists*
chemical_list: D000276:Adjuvants, Immunologic; D019496:Cancer Vaccines; D051193:Toll-Like Receptors
keywords: Biological agent; Immunotherapy; Oncology; Optimal dose; Phase I/II
references: J Clin Oncol. 2001 Mar 15;19(6):1848-54
references: 11251017
references: J Clin Oncol. 2008 Aug 1;26(22):3665-7
references: 18669449
references: Stat Med. 2005 Jul 30;24(14):2171-81
references: 15909289
references: J Immunol. 2009 Jun 15;182(12):7398-407
references: 19494262
references: J Natl Cancer Inst. 2009 May 20;101(10):708-20
references: 19436029
references: Chin Clin Oncol. 2014 Mar;3(1):2
references: 25842080
references: Clin Cancer Res. 2009 Nov 15;15(22):7036-44
references: 19903780
references: Trends Immunol. 2013 Feb;34(2):90-8
references: 23031830
references: Stat Med. 2014 May 30;33(12):1990-2003
references: 24470329
references: Clin Cancer Res. 2014 Sep 15;20(18):4758-67
references: 25037736
references: Stat Med. 2011 Jul 30;30(17):2062-9
references: 21351287
references: Clin Cancer Res. 2010 Mar 15;16(6):1710-8
references: 20215546
references: J Natl Cancer Inst. 2004 Jul 7;96(13):990-7
references: 15240782
references: Biometrics. 2008 Mar;64(1):232-41
references: 17573866
references: J Biopharm Stat. 2015;25(5):903-20
references: 24904956
references: J Clin Oncol. 2011 Jul 20;29(21):2924-32
references: 21690475
references: Cancer Res. 2012 Feb 1;72(3):581-91
references: 22158905
references: Clin Trials. 2014 Jun;11(3):319-327
references: 24844841
references: Clin Trials. 2009 Jun;6(3):227-38
references: 19528132
references: J Clin Oncol. 2014 Aug 10;32(23):2505-11
references: 24982451
references: Biometrics. 2013 Sep;69(3):673-82
references: 23957592
references: J Biopharm Stat. 2012;22(4):785-801
references: 22651115
references: Biometrics. 1990 Mar;46(1):33-48
references: 2350571
references: Clin Trials. 2011 Aug;8(4):380-9
references: 21652689
references: J Natl Cancer Inst. 2004 Jul 7;96(13):977-8
references: 15240771
references: Stat Med. 2006 Jul 30;25(14):2365-83
references: 16220478
references: J Biopharm Stat. 2010 Sep;20(5):1013-25
references: 20721788
references: Cancer Chemother Pharmacol. 2013 May;71(5):1107-14
references: 23299793
references: Clin Cancer Res. 2007 Nov 1;13(21):6386-95
references: 17975151